Target Multi-Billion Dollar ``Mold'' Opportunity

[Guest guest]

http://home.businesswire.com/portal/site/google/index.jsp?

ndmViewId=news_view & newsId=20040927005138 & newsLang=en

September 27, 2004 08:30 AM US Eastern Timezone

Veridien And Partner Target Multi-Billion Dollar ``Mold'' Opportunity

ST. PETERSBURG, Fla.--(BUSINESS WIRE)--Sept. 27, 2004--Veridien

Corporation announced today that its R & D strategic partner - North

Carolina-based Mycosol, Inc. - has embarked on the regulatory path to

approve two of its proprietary chemical compounds for mold prevention

in - and remediation of - building structures. Unchecked, mold is

already causing billions of dollars in property damage and has been

purported to cause or exacerbate illness in humans and household

animals. According to the Insurance Information Institute

(http://www.iii.org), " Concern about the consequences of mold

contamination has become one of today's top subjects. The

implications of the emerging mold issue for insurance and the economy

are serious. " In fact, the Institute's August 2003 paper on Mold and

Insurance states " US insurers paid out at least $3 billion in mold-

related claims in 2002, more than double the $1.3 billion paid the

previous year. " After receiving excellent anti-fungal results from

ongoing, broad spectrum testing against deleterious molds, Mycosol

targeted what it believes to be a significant and growing need for

the pre- and post-treatment of construction materials and dwellings.

These collective, multi-billion dollar commercial applications

include the treatment of: wallboard, lumber, plywood, flooring,

decking, siding, filters, HVAC systems, and myriad of other building

supplies and surfaces. According to Mycosol's President and Chief

Scientific Officer, Jeff Selph, " our platform technology and library

of over 1,500 unique chemical compounds appear to have the ideal

characteristics to be effective and potent anti-mold agents:

fungistatic and fungicidal yet environmentally safe, long-term

durability, non-water soluble, non-volatile, and a very cost

effective manufacturing process. Now that our two lead compounds have

been identified through preliminary testing, we have begun the

rigorous process of formal safety and efficacy testing required for

EPA approval . . . a process which is expected to be completed within

two years. "

Veridien and Mycosol have initiated discussions with potential

strategic partners, who may wish to participate in the distribution

of this anti-mold technology and related products in their specific

market segments.

Veridien recently entered into a comprehensive strategic alliance

with Mycosol in which Veridien has invested, and has the right to

acquire the majority interest of this chemical and pharmaceutical

development company. Mycosol will serve as Veridien's technology

discovery and development arm. In addition, Mycosol's senior

executives are working with Veridien to provide operational,

technical, and product development support to expand the current

Viraguard anti-infectives product portfolio, create new products, and

increase market penetration.

Sheldon C. Fenton, President and C.E.O. of Veridien Corporation

stated: " Veridien's mission is to be a leader in the anti-infectives

market through the development and commercialization of technologies,

products, and services which eliminate or greatly reduce harmful

microbials in our working and living environment. While our current

products effectively kill bacteria, viruses, and fungi - such as mold

and mildew - the new Mycosol technology should provide us with an

expanded arsenal of proprietary, safe, broad spectrum, long-term anti-

mold, anti-bacterial agents. "

About Veridien:

Veridien Corporation is a Health Care and Anti-Infectives Company

focusing on Infection Control and other Healthy Lifestyle products.

Veridien has developed patented and unique products including surface

disinfectants, antiseptic hand cleansers, instrument presoak, and sun

protectant products. The flagship product, Viraguard® Hospital

Disinfectant/Cleaner and Instrument Presoak is a skin friendly,

patented, U.S. - EPA and Health Canada registered, surface

disinfectant. Viraguard® Antiseptic Hand Gel, Viraguard®

Antiseptic Hand Spray and Viraguard® Antiseptic Hand Wipes are

U.S. - FDA and Health Canada drug listed products utilizing

Veridien's patented Virahol® formulation.

Look for Veridien at http://www.veridien.com

About Veridien's investment in future technology:

Mycosol is a development-stage chemical and pharmaceutical company

based in the Research Triangle Park area of North Carolina. The

Company is developing a proprietary, low cost platform technology to

safely and effectively treat and prevent microbial-induced and

microbial-exacerbated problems. Mycosol's proprietary, multi-active

compound(s) have demonstrated potent anti-fungal, anti-bacterial,

anti-inflammatory, and anti-allergic properties. Using this 'core

technology' platform, plus a library of over 1,500 known analogs and

5 patents pending, Mycosol believes that a broad portfolio of

products can be developed for many medical, industrial, veterinary,

and agricultural applications.

Look for Mycosol at http://www.mycosol.com

Special Note: Forward-looking statements in this press release are

made pursuant to the " safe-harbor " provisions of the Private

Securities Litigation Reform Act of 1995. Investors are cautioned

that such forward-looking statements involve risks and uncertainties,

including without limitation, market acceptance of, and demand for,

the Company's products, manufacturing, development and distributor

issues, product pricing, competition, funding availability,

technological changes and other risks not identified herein. The

Company disclaims any intent or obligation to update any forward-

looking statements.

" Healthy Living is an Adventure - Let Veridien Guide You "

Contacts

Veridien Corporation, St. sburg

Cheryl Ballou, 727-576-1600 x202

cballou@...